Remission or Not Remission, That ’s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis
ConclusionsSince PGA is strongly associated with the patient ’s perception of pain and may not reflect the inflammatory process, our study challenges the application of remission-assessing methods containing PGA when monitoring RA patients in the outpatient clinic. We recommend using measures that are less likely to be associated with noninflammatory pain a nd psychosocial factors. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 21, 2022 Category: Rheumatology Source Type: research
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials
ConclusionsUpadacitinib, as monotherapy or in combination with csDMARDs, was associated with patient-reported remission assessed by RAPID3 over 60 weeks across the SELECT RCTs in patients with RA.Trial registrationSELECT-BEYOND (NCT02706847); SELECT-NEXT (NCT02675426); SELECT-MONOTHERAPY (NCT02706951); SELECT-EARLY (NCT02706873); SELECT-COMPARE (NCT02629159). (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 20, 2022 Category: Rheumatology Source Type: research
Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sj ögren’s
ConclusionsThe findings support use of ESSDAI and ESSPRI as Sj ögren’s clinical trials endpoints, as well as in clinical practice and other research settings. Qualitative data exploring meaningful change supports existing minimal clinically important improvement (MCII) thresholds. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2022 Category: Rheumatology Source Type: research
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
ConclusionsThe majority of the effect of tofacitinib on pain was collectively mediated by itch, CRP, and enthesitis, with itch being the primary mediator of treatment effect.Trial Registration: NCT01877668, NCT01882439.Graphical PLS (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 8, 2022 Category: Rheumatology Source Type: research
Correction: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 7, 2022 Category: Rheumatology Source Type: research
Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study
ConclusionsIn a real-world setting, patients with active PsA who received ustekinumab until 160 weeks (3 years), including those who received prior biologic therapies, had a rapid onset of effect and sustained response to treatment, with high tolerability.Trial registrationPEI NIS No. 290. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 6, 2022 Category: Rheumatology Source Type: research
Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 5, 2022 Category: Rheumatology Source Type: research
Febuxostat Therapy for Patients with Gout and Stage 2 –4 CKD: a Retrospective Study
ConclusionsFebuxostat demonstrated efficacy and renal safety in patients with gout and CKD in clinical practice. Achieving the target SU could obviously improve renal function. Baseline SU level and body weight could affect the achievement of target SU. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 3, 2022 Category: Rheumatology Source Type: research
Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada
ConclusionThis study identified substantial differences in patient baseline characteristics. Patients on injectable biologics were more likely to be adherent compared with those on oral drugs, possibly owing to longer dosing intervals. Other outcomes at 12 months appeared similar as evidenced by tapering of concomitant medications, although differences in persistence and dose escalation were noted. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 1, 2022 Category: Rheumatology Source Type: research
Successful Chemical Synovectomy in a Patient with Acquired von Willebrand Syndrome with Chronic Synovitis Due to Recurrent Knee Hemarthrosis: A Case Report
We describe the clinical course of a 62-year-old man with polycythemia vera who experienced post-traumatic knee and leg swelling due to hemarthrosis. He was treated at another center with low molecular weight heparin due to misdiagnosed deep vein thrombosis further exacerbating the ongoing bleeding. At our center, he was diagnosed with AVWS with reduced von Willebrand factor (VWF):GPIbR plasma activity and loss of high molecular weight multimers (HMWM). He was treated with compressive bandages with resolution. Five months later, on clinical recurrence of knee and leg swelling, knee ultrasound scan showed the presence of ch...
Source: Rheumatology and Therapy - August 10, 2022 Category: Rheumatology Source Type: research
Development and Validation of a Machine Learning-Based Nomogram for Prediction of Ankylosing Spondylitis
ConclusionOur ML model can satisfactorily predict patients with AS. This nomogram can help orthopedic surgeons devise more personalized and rational clinical strategies. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 6, 2022 Category: Rheumatology Source Type: research
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
ConclusionsRisankizumab improved joint and skin symptoms versus placebo in patients with active PsA over 16 weeks; improvements were sustained long term. Risankizumab was well tolerated over the long term with no new safety findings.Trial Registration NumbersNCT02719171 and NCT02986373. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - August 5, 2022 Category: Rheumatology Source Type: research
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
ConclusionThese data demonstrate that serum collagen biomarkers are elevated in patients with PsA compared with healthy controls and that treatment with guselkumab decreases levels of C1M, C3M, C4M, and C6M. Importantly, C1M serves as a biomarker that associates with improvement of joint signs and symptoms.Trial RegistrationClinicalTrials.gov identifier: NCT03158285. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - July 25, 2022 Category: Rheumatology Source Type: research
Characteristics of Patients with Primary Sj ögren’s Syndrome and Non-specific Chronic Sialadenitis: A Subtype in Elderly Patients
ConclusionsThe pSS patients with NSCS were older than corresponding non-NSCS pSS individuals, but they had similar clinical features. NSCS is associated with age and seldom occurred below the age of 45 years, regardless of the presence or absence of pSS. NSCS may be a subtype of pSS in elderly patients. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - July 22, 2022 Category: Rheumatology Source Type: research
Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-of-the-Art Review
AbstractInvestigation of the potential applications of artificial intelligence (AI), including machine learning (ML) and deep learning (DL) techniques, is an exponentially growing field in medicine and healthcare. These methods can be critical in providing high-quality care to patients with chronic rheumatological diseases lacking an optimal treatment, like rheumatoid arthritis (RA), which is the second most prevalent autoimmune disease. Herein, following reviewing the basic concepts of AI, we summarize the advances in its applications in RA clinical practice and research. We provide directions for future investigations in...
Source: Rheumatology and Therapy - July 18, 2022 Category: Rheumatology Source Type: research
